What is Gyre Therapeutics, Inc.'s stock-based comp?

Gyre Therapeutics, Inc. (GYRE) reported stock-based comp of $2.58M in Q1 2026.

How has Gyre Therapeutics, Inc.'s stock-based comp changed year-over-year?

Gyre Therapeutics, Inc.'s stock-based comp increased by 409.5% year-over-year, from $507K to $2.58M.

What is the long-term trend for Gyre Therapeutics, Inc.'s stock-based comp?

Over 4 years (2021 to 2025), Gyre Therapeutics, Inc.'s stock-based comp has grown at a 20.4% compound annual growth rate (CAGR), from $3.41M to $7.16M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Gyre Therapeutics, Inc. GYRE Stock-Based Comp

Stock-Based Comp at other companies

Eli LillyLLY

$161M+4.5%

Madrigal Pharmaceuticals, Inc.MDGL

$34.02M+62.5%

Viking TherapeuticsVKTX

$10.34M-8.9%

Theravance BiopharmaTBPH

$4.5M-7.6%

Rigel PharmaceuticalsRIGL

$3.46M+4.0%

Zevra Therapeutics, Inc.ZVRA

$3.11M-0.3%

Segments

By segment

See full

Gyre Pharmaceuticals$1.71M+2,096%

Gyre$870K+103%

All Other Segments$0—

Other financials

Income statement

See full

Revenue$22.5M+2.1%

Gross profit$21.3M+0.6%

Operating income-$9.4M-512%

Net income-$8.7M-422%

EPS (diluted)-$0.10—

Balance sheet

See full

Cash & equivalents$37.5M+149%

Total debt$823.0K-48.1%

Total equity$101.3M+48.7%

Total assets$162.0M+24.8%

Cash flow

See full

Operating cash flow$3.2M+2,565%

CapEx$178.0K+45.9%

Free cash flow$3.0M+1,296%

Valuation

See full

Market cap$694.58M-4.7%

Enterprise value$657.9M-8.0%

P/S5.9×-1.3×

Profitability

See full

Gross margin95.1%-1.1pp

Operating margin-0.1%-10.4pp

Net margin6.3%+3.3pp

FCF margin2.6%—

Returns & leverage

See full

Return on equity8.2%+4.2pp

Debt / equity0×0.0×

Current ratio4.6×+1.0×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s stock-based comp?: Gyre Therapeutics, Inc. (GYRE) reported stock-based comp of $2.58M in Q1 2026.
How has Gyre Therapeutics, Inc.'s stock-based comp changed year-over-year?: Gyre Therapeutics, Inc.'s stock-based comp increased by 409.5% year-over-year, from $507K to $2.58M.
What is the long-term trend for Gyre Therapeutics, Inc.'s stock-based comp?: Over 4 years (2021 to 2025), Gyre Therapeutics, Inc.'s stock-based comp has grown at a 20.4% compound annual growth rate (CAGR), from $3.41M to $7.16M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.